文献速递糖尿病肥胖与代谢综合征

胰高血糖素样肽-1药物治疗2型糖尿病与肥胖的疗效与安全性

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity.
PubMed 文献 · Diabetes Care · 2024-01-01

本文综述了GLP-1受体激动剂(GLP-1RA)在2型糖尿病和肥胖治疗中的疗效证据及心脏肾脏获益,并讨论了基于GLP-1的新分子实体(如替尔泊肽、玛利肽、瑞他鲁肽、苏沃度肽)的研发进展。同时重点讨论了安全性数据,涉及肌肉力量、骨密度与骨折、运动能力、胃肠动力、胃内容物残留与麻醉、胰腺和胆道疾病及癌症风险。

要点

  • GLP-1RA在特定患者人群中已建立心脏肾脏获益证据。
  • 基于GLP-1的药物成功推动了新分子实体和联合疗法的开发。
  • 安全性讨论涵盖肌肉、骨骼、胃肠动力、胰腺胆道及癌症风险。

核心结论

  • 基于GLP-1的高效药物快速进展及新药在代谢疾病亚群中的预期分化,将为个性化医疗提供更多机会以改善心血管代谢疾病患者的健康。

研究设计与样本

  • 本文为叙述性综述,检索范围未在摘要中报告。

主要发现

  • GLP-1RA在2型糖尿病和肥胖患者中显示出疗效,并在特定患者群体中具有心脏肾脏获益。
  • 替尔泊肽是GIP-GLP-1受体共激动剂;玛利肽阻断GIP并激活GLP-1受体;瑞他鲁肽和苏沃度肽可同时激活胰高血糖素和GLP-1受体。
  • 正在进行的试验探索GLP-1药物用于代谢性肝病、外周动脉疾病、帕金森病和阿尔茨海默病等新适应症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1-based medicines has spurred the development of new molecular entities and combinations with unique pharmacokinetic and pharmacodynamic profiles, exemplified by tirzepatide, a GIP-GLP-1 receptor coagonist. Simultaneously, investigational molecules such as maritide block the GIP and activate the GLP-1 receptor, whereas retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. Here I highlight evidence establishing the efficacy of GLP-1-based medicines, while discussing data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024. PMID: 38843460. doi:10.2337/dci24-0003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。